TY - JOUR
T1 - Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
AU - Takamatsu, Hiroyuki
AU - Yamashita, Takeshi
AU - Kurahashi, Shingo
AU - Saitoh, Takayuki
AU - Kondo, Tadakazu
AU - Maeda, Takeshi
AU - Nakazawa, Hideyuki
AU - Murata, Makoto
AU - Narita, Tomoko
AU - Kuroda, Junya
AU - Hashimoto, Hisako
AU - Kawamura, Koji
AU - Miyamoto, Toshihiro
AU - Honda, Sumihisa
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Sunami, Kazutaka
N1 - Funding Information:
Conflict of interest statement: H.T. has received research funding from Bristol-Myers Squibb, Ono, and Celgene and honoraria from Janssen and Celgene. J.K. has received research funding from Celgene and Fujimoto and honoraria from Janssen and Celgene. K.S. has received research funding from MSD, Celgene, AbbVie, Takeda, Sanofi, and Bristol-Myers Squibb and honoraria from Ono, Celgene, and Bristol-Myers Squibb. The other authors have no conflicts of interest to report.
Funding Information:
Financial disclosure: The authors have nothing to disclose. Conflict of interest statement: H.T. has received research funding from Bristol-Myers Squibb, Ono, and Celgene and honoraria from Janssen and Celgene. J.K. has received research funding from Celgene and Fujimoto and honoraria from Janssen and Celgene. K.S. has received research funding from MSD, Celgene, AbbVie, Takeda, Sanofi, and Bristol-Myers Squibb and honoraria from Ono, Celgene, and Bristol-Myers Squibb. The other authors have no conflicts of interest to report. A complete list of the investigators in this study is provided in Supplementary Data. Financial disclosure: See Acknowledgments on page 479.
Publisher Copyright:
© 2018 American Society for Blood and Marrow Transplantation
PY - 2019/3
Y1 - 2019/3
N2 - Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m 2 melphalan between 2001 and 2011. The patients were grouped according to chromosomal abnormality, including t(11;14) (n = 45), t(4;14) (n = 31), del 17p (n = 10), t(11;14) with del 17p (n = 7), and t(4;14) with del 17p (n = 4). Median overall survival (OS) of the t(11;14) group (64.1 months) was not significantly different from that of the t(4;14) group (not reached), but it was significantly longer than that of the del 17p group (23.0 months; P =.002). G-banding revealed that the median OS of the t(11;14) group with additional chromosomal abnormalities (ACAs) (46.2 months) was significantly shorter than that of the t(11;14) group without ACAs (not reached; P =.005) and the t(4;14) group (not reached; P =.010). These findings highlight the importance of G-banding in patients with t(11;14) MM.
AB - Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m 2 melphalan between 2001 and 2011. The patients were grouped according to chromosomal abnormality, including t(11;14) (n = 45), t(4;14) (n = 31), del 17p (n = 10), t(11;14) with del 17p (n = 7), and t(4;14) with del 17p (n = 4). Median overall survival (OS) of the t(11;14) group (64.1 months) was not significantly different from that of the t(4;14) group (not reached), but it was significantly longer than that of the del 17p group (23.0 months; P =.002). G-banding revealed that the median OS of the t(11;14) group with additional chromosomal abnormalities (ACAs) (46.2 months) was significantly shorter than that of the t(11;14) group without ACAs (not reached; P =.005) and the t(4;14) group (not reached; P =.010). These findings highlight the importance of G-banding in patients with t(11;14) MM.
UR - http://www.scopus.com/inward/record.url?scp=85059044521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059044521&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2018.11.003
DO - 10.1016/j.bbmt.2018.11.003
M3 - Article
C2 - 30423479
AN - SCOPUS:85059044521
SN - 1083-8791
VL - 25
SP - 474
EP - 479
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 3
ER -